Key result
Tetriflex sirolimus-eluting stent achieves a 2.5% 6-month composite event rate in CAD.
Why the study?
Despite various drug-eluting stents, the search for an ideal stent is ongoing, prompting evaluation of the safety and clinical outcomes of the Tetriflex ultrathin biodegradable polymer-coated SES.
Observational (n=1,269)
Yes
Answers are grounded in this paper and cite their sources.
The ultrathin biodegradable polymer-coated Tetriflex sirolimus-eluting stent demonstrated favorable safety and efficacy with low rates of target-lesion revascularization and stent thrombosis at 6 months in a real-world CAD population.
BACKGROUND: Although a number of drug-eluting stents have been developed with different design, composition, and polymers, the search for an ideal drug-eluting stent is ongoing. The Tetriflex (Sahajanand Medical Technology, Surat, India) is a newer-generation, ultrathin (60 µm) biodegradable polymer-coated sirolimus-eluting stent (SES) designed with a unique long dual Z-link on a cobalt-chromium alloy. The present registry aimed to evaluate the safety and clinical outcomes of the Tetriflex SES at 6-month post-implantation. METHODS: This was an investigator-initiated, retrospective, multicenter, single-arm, observational registry conducted at five tertiary-care centers in India. A total of 1,269 consecutive patients with coronary artery disease who underwent implantation of at least one Tetriflex SES between March 2017 and March 2018 were included. The primary outcome was considered a composite of cardiac death, myocardial infarction and target-lesion revascularization (TLR) at 6-month follow-up. Stent thrombosis was evaluated as a safety outcome at 6-month follow-up. RESULTS: The mean age of patients was 54.99±10.80 years. Among 1,515 lesions treated with 1,682 Tetriflex SES, 58.3% were type C lesions. Six-month follow-up was done for 1,245 of 1,269 (98.1%) patients. At 6 months, composite events had occurred in 31 (2.5%) patients, consisting of ten (0.8%) cardiac deaths, 16 (1.3%) myocardial infarctions, and five (0.4%) TLRs. Stent thrombosis was observed in seven (0.56%) cases at 6 months. A subgroup analysis between diabetic and nondiabetic patients did not reveal any statistically significant difference for clinical outcomes at 6-month follow-up. CONCLUSION: The results of the current registry outline the safety and effectiveness of the Tetriflex SES in real-world patients, as it displayed favorable clinical outcomes at 6-month follow-up, with low incidence of TLR and stent thrombosis.
No takes yet. Share an insight, caveat, or question.
Ajmera et al. (2019) conducted an observational in Coronary artery disease (n=1,269). Tetriflex sirolimus-eluting stent was evaluated on Composite of cardiac death, myocardial infarction, and target-lesion revascularization at 6 months. In real-world patients with coronary artery disease, implantation of the Tetriflex sirolimus-eluting stent resulted in a 2.5% composite rate of cardiac death, myocardial infarction, and target-lesion revascularization at 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: